By Karima Yadi, Global Marketing Lead for the Autoinjector Platform, and Lionel Maritan, Senior Program Manager, Autoinjectors Platform, BD Medical – Pharmaceutical Systems
In this article, Karima Yadi, Global Marketing Lead for the Autoinjector Platform, and Lionel Maritan, Senior Program Manager, Autoinjectors Platform, both at BD Medical – Pharmaceutical Systems, discuss BD’s response to the need for an autoinjector platform that reconciles the demands of biologics with safety, reliability and ease of use during self-injection: the Intevia™ 2.25 mL disposable autoinjector.
Multi-disciplinary teams at BD set out to develop an autoinjector platform that builds on past successes, while meeting the requirements of the highly viscous, high volume1 biologics that are upcoming in the chronic disease space. The result is an autoinjector platform that delivers an enhanced experience for patients,2 extends the design space beyond traditional subcutaneous (SC) delivery for biologics and can lower development risks for biopharmaceutical partners.
Chronic diseases represent a major burden to the healthcare system, accounting for approximately 77% of the total disease burden and 86% of all deaths in Europe.3 Today, innovative drug therapies, such as biologics, are contributing towards an improvement in the quality of life for chronic disease sufferers. Simultaneously, innovations in the drug delivery device space are making it possible for chronic disease sufferers to manage their drug therapies from home.4 Subsequently, many innovations in this area seek to improve the patient self-injection experience by addressing issues, such as injection frequency, pain perception, needle phobia, needlestick injuries, accidental intramuscular (IM) injection risk and dose accuracy and consistency. Beyond greater comfort and convenience for patients, moving the centre of care from the clinic to the home, when possible, contributes to better management of healthcare costs.1